Chronic renal failure patients receiving hemodialysis
Conditions
Interventions
Probiotics products administration group: BIO-THREE(6g/day, 6 tablets) will be administered 3 times after each meal daily for 24 weeks.
Placebo administration group: Placebo(6g/day, 6 tablets) will
Sponsors
Tokyo Women's Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Patients who have received hemodialysis for more than 3 month. 2 Patinets who have received hemodialysis in the medical institutions conducting this examination
Exclusion criteria
Exclusion criteria: 1 Patients who received peritoneal dialysis 2 Patients whose serum CRP levels were 1.0 mg/dl and over within 1 week 3 Patients who took ethical drugs including probiotics within 1 week 4 Patients with an infection or a sign of an infection within 1 week 5 Patients with an inflammatory disease or a sign of an inflammatory disease 6 Patients with a past history of hypersensitivity to BIO-THREE component 7 Patients considered as inadequate human subjects by the principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the changes of the ratio of CRP to albumin before and after administration of probiotics products. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Intestinal flora (next generation sequence) 2. ALP isozyme 3. Serum level of ALP 4. The small intestine gas | — |
Countries
Japan
Contacts
Public ContactOgawa Tetsuya
Tokyo Women's Medical University Medical Center East Blood Purification
Outcome results
None listed